HCCI | Benzinga’s Top Upgrades, Downgrades For October 19, 2020

Upgrades According to Guggenheim, the prior rating for Bristol-Myers Squibb Company (NYSE: BMY ) was changed from Neutral to Buy.For the second quarter, Bristol-Myers Squibb had an EPS of $1.63, compared to year-ago quarter EPS of $1.18.At the moment, the stock has a 52-week-high of 68.34 and a 52-week-low of 45.76.Bristol-Myers Squibb closed at $61.25 […]